SRSF3 is often upregulated in clinical glioma specimens, and it has been demonstrated that high SRSF3 is associated with tumor progression and a bad prognosis for glioma patients (Song et al., 2019). The gene discussed is SRSF3; the disease is central nervous system cancer.